PubMed Journals Articles About "Dolutegravir Infection" RSS

00:11 EST 24th February 2020 | BioPortfolio

Dolutegravir Infection PubMed articles on BioPortfolio. Our PubMed references draw on over 21 million records from the medical literature. Here you can see the latest Dolutegravir Infection articles that have been published worldwide.

More Information about "Dolutegravir Infection" on BioPortfolio

We have published hundreds of Dolutegravir Infection news stories on BioPortfolio along with dozens of Dolutegravir Infection Clinical Trials and PubMed Articles about Dolutegravir Infection for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Dolutegravir Infection Companies in our database. You can also find out about relevant Dolutegravir Infection Drugs and Medications on this site too.

Showing "Dolutegravir infection" PubMed Articles 1–25 of 7,700+

Dolutegravir plus Two Different Prodrugs of Tenofovir to Treat HIV.

Two drugs under consideration for inclusion in antiretroviral therapy (ART) regimens for human immunodeficiency virus (HIV) infection are dolutegravir (DTG) and tenofovir alafenamide fumarate (TAF). There are limited data on their use in low- and middle-income countries.

Dolutegravir/Lamivudine Single-Tablet Regimen: A Review in HIV-1 Infection.

The oral once-daily, fixed-dose single-tablet regimen (STR) of dolutegravir/lamivudine (Dovato), combining a second generation integrase single-strand transfer inhibitor (INSTI) and a nucleoside reverse transcriptase inhibitor (NRTI), is indicated as a complete regimen for the treatment of HIV-1 infection in adults and adolescents (> 12 years of age weighing at least 40 kg) with no known or suspected resistance to the INSTI class or lamivudine. In GEMINI trials in antiretroviral therapy (ART)-naïve HIV...

Safety and pharmacokinetics of dolutegravir in pregnant mothers with HIV infection and their neonates: A randomised trial (DolPHIN-1 study).

The global transition to use of dolutegravir (DTG) in WHO-preferred regimens for HIV treatment is limited by lack of knowledge on use in pregnancy. Here we assessed the relationship between drug concentrations (pharmacokinetics, PK), including in breastmilk, and impact on viral suppression when initiated in the third trimester (T3).

Prediction of dolutegravir pharmacokinetics and dose optimization in neonates via physiologically based pharmacokinetic (PBPK) modelling.

Only a few antiretroviral drugs (ARVs) are recommended for use during the neonatal period and there is a need for more to be approved to increase treatment and prophylaxis strategies. Dolutegravir, a selective integrase inhibitor, has potential for treatment of HIV infection and prophylaxis of transmission in neonates.

Placental transfer and tissue accumulation of dolutegravir in the ex vivo human cotyledon perfusion model.

To determine the transplacental pharmacokinetics of the HIV integrase inhibitor dolutegravir.

Dolutegravir-Based or Low-Dose Efavirenz-Based Regimen for the Treatment of HIV-1.

An efavirenz-based regimen (with a 600-mg dose of efavirenz, known as EFV600) was the World Health Organization preferred first-line treatment for human immunodeficiency virus type 1 (HIV-1) infection until June 2018. Given concerns about side effects, dolutegravir-based and low-dose efavirenz-based combinations have been considered as first-line treatments for HIV-1 in resource-limited settings.

Dolutegravir/lamivudine (Dovato)--a two-drug complete regimen for HIV-1 infection.

Successful use of once-daily high-dose darunavir and dolutegravir in multidrug-resistant HIV.

WHAT IS KNOWN AND OBJECTIVE?: Antiretroviral (ARV) resistance may result during periods of consistently poor adherence. We report the successful use of a novel once-daily (QD) ARV regimen in a patient with multidrug-resistant (MDR) HIV. CASE SUMMARY: Once-daily darunavir 1200 mg/ritonavir 100 mg, dolutegravir and emtricitabine/tenofovir alafenamide was initiated with directly observed therapy. With the assistance of therapeutic drug monitoring, dolutegravir dosing was increased to 150 mg daily. The patie...

Single tablet regimen with abacavir/lamivudine/dolutegravir compared with two-drug regimen with lamivudine and dolutegravir as different strategies of simplification from a multicenter HIV cohort study.

We investigated the effectiveness and safety of a dual therapy (DT) with lamivudine plus dolutegravir versus a single tablet regimen (STR) with abacavir/lamivudine/dolutegravir. We performed a retrospective analysis in a cohort of virologically suppressed HIV+ patients switching to lamivudine-dolutegravir or abacavir/lamivudine/dolutegravir. We evaluated the incidence of virological failure and treatment discontinuation, as well as their predictors. Non-parametric tests were applied to assess changes in imm...

Long term data on the efficacy and tolerability of lamivudine plus dolutegravir as a switch strategy in a multicenter cohort of HIV1-infected, virologically suppressed patients.

Results from clinical trials and observational studies suggest that lamivudine plus dolutegravir could be an effective and tolerated option for simplification in HIV-1 positive patients.

Updated assessment of risks and benefits of dolutegravir versus efavirenz in new antiretroviral treatment initiators in sub-Saharan Africa: modelling to inform treatment guidelines.

The integrase inhibitor dolutegravir is being considered in several countries in sub-Saharan Africa instead of efavirenz for people initiating antiretroviral therapy (ART) because of superior tolerability and a lower risk of resistance emergence. WHO requested updated modelling results for its 2019 Antiretroviral Guidelines update, which was restricted to the choice of dolutegravir or efavirenz in new ART initiators. In response to this request, we modelled the risks and benefits of alternative policies for...

Retrospective Study On The Outcomes Of Two-drugs Regimens Based On Dolutegravir Plus One Reverse Transcriptase Inhibitor In Virologically Suppressed, HIV-Infected Patients.

To evaluate efficacy and drug-resistance mutations selected at virological failure (VF) in HIV-infected patients switched to dolutegravir plus rilpivirine (DTG+RPV) or lamivudine (DTG+3TC) while virologically suppressed.

Boosted darunavir and dolutegravir dual therapy among a cohort of highly treatment-experienced individuals.

The use of dual antiretroviral therapy (ART) regimens for treatment of HIV is increasing. The contemporary combination of boosted darunavir with dolutegravir has not been widely studied.

Clinical and virological outcomes of TB/HIV co-infected patients treated with dolutegravir-based HIV antiretroviral regimens: Programmatic experience from Botswana.

Dolutegravir (DTG) has recently been recommended as a preferred first-line regimen for the treatment of new and treatment experienced HIV infected patients. However, potential drug interactions between DTG and rifampicin remain a clinical and public health concern.

Immune recovery markers in a double blind clinical trial comparing dolutegravir and raltegravir based regimens as initial therapy (SPRING-2).

Multiple T-cell marker recovery (MTMR: CD4+ T-cells >500 cel/mm3 plus CD4+% >29% plus CD4+/CD8+ ratio >1) has been proposed as the most complete level of immune reconstitution. In this study we quantified differences in the CD4+/CD8+ ratio, CD4+% recovery and MTMR after starting HIV-1 treatment with dolutegravir (DTG) vs. raltegravir (RAL) plus a NRTI backbone.

M184V/I does not impact the efficacy of abacavir/lamivudine/dolutegravir use as switch therapy in virologically suppressed patients.

M184V/I NRTI resistance mutations can be selected by either lamivudine/emtricitabine or abacavir. There are controversies about the use of abacavir/lamivudine/dolutegravir combinations in HIV-1-infected treatment-experienced patients with a fully suppressed HIV viral load (VL) and harbouring M184V/I.

Efficacy and Safety of Switching to Dolutegravir/Lamivudine Fixed-Dose Two-Drug Regimen Versus Continuing a Tenofovir Alafenamide-Based Three- or Four-Drug Regimen for Maintenance of Virologic Suppression in Adults With HIV-1: Phase 3, Randomized, Non-inferiority TANGO Study.

The 2-drug regimen (2DR) dolutegravir (DTG) + lamivudine (3TC) is indicated for treatment-naive adults with HIV-1. We present efficacy and safety of switching to DTG/3TC in virologically suppressed individuals.

Two-drug regimens with dolutegravir plus rilpivirine or lamivudine in HIV-1 treatment-naïve, virologically-suppressed patients: latest evidences from the literature on their efficacy and safety.

In HIV-positive population, a paradigm shift from three-drug regimens to dolutegravir-based two-drug regimens as both initial and switch treatment approach is beginning to take place, virologically supported by the availability of new, potent drugs with high genetic-barrier that allow to overcome, at least in certain conditions, the dogma of three-drug regimens in HIV-effective therapy. Indeed, there is increasing evidence on their excellent and sustained long-term effectiveness and safety, that this manusc...

Mathematical modeling of HIV-1 transmission risk from condomless anal intercourse in HIV-infected MSM by the type of initial ART.

Initiation of antiretroviral therapy (ART) for HIV infection using regimens that include integrase strand transfer inhibitors (INSTIs) is associated with a faster decline in HIV-1 RNA than what is observed with regimens that are anchored by other ART drug classes. We compared the impact of ART regimens that include dolutegravir (DTG), raltegravir (RAL), efavirenz (EFV), or darunavir/ritonavir (DRV/r), in treatment naïve men who have sex with men (MSM) on the probability of HIV-1 sexual transmission events ...

More evidence for dolutegravir as first-line ART for all.

Use of Dolutegravir for Antiretroviral Therapy for Women of Childbearing Age.

The purpose of this article is to offer an update on the use of antiretroviral therapy (ART) for HIV among women of childbearing age. We focus specifically on the use of dolutegravir (DTG) because of a recently identified potential safety issue related to neural tube defects in the fetuses of women who used DTG at the time of conception. Nurses and advanced practice registered nurses should engage in shared decision-making processes for reproductive life planning with women of childbearing age who are livin...

Analysis of Pharmacovigilance Databases for Dolutegravir Safety in Pregnancy.

The Botswana Tsepamo study reported neural tube defects (NTDs) in 4 of 426 (0.94%) infants of women receiving preconception dolutegravir (DTG) antiretroviral therapy (ART) vs 14 of 11 300 (0.12%) receiving preconception non-DTG ART. Data are needed to investigate this potential safety signal. Clinicians, patients, and pharmaceutical companies can report adverse drug reactions (ADRs) to pharmacovigilance databases. Data from ADRs reported to various pharmacovigilance databases were searched for NTDs.

Failure of Dolutegravir First-Line ART with Selection of Virus Carrying R263K and G118R.

Postmarketing Surveillance of Pregnancy Outcomes With Dolutegravir Use.

Acute myocarditis after switch to dolutegravir: a reminder of potential toxicity of integrase inhibitor-including HAART.

Quick Search